Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImExHSASX:IME 48 Cash-to-Debt is 5.83 as of Dec. 2025, which is 87% above its 10-year median of 3.12. GuruFocus rates ASX:IME with a GF Score™ of 48/100 and a GF Value™ of A$0.51 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 209 Medical Diagnostics & Research companies, ImExHS ranks better than 74.16% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ImExHS's cash to debt ratio for the quarter that ended in Dec. 2025 was 5.83.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, ImExHScould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for ImExHS's Cash-to-Debt or its related term are showing as below:
ASX:IME'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.75 Med: 3.12 Max: No Debt
Current: 5.83
During the past 13 years, ImExHS's highest Cash to Debt Ratio was No Debt. The lowest was 0.75. And the median was 3.12.
ASX:IME's Cash-to-Debt is ranked better than 74.16% of 209
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.13
vs ASX:IME: 5.83
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
ImExHS Cash-to-Debt Related Terms
ImExHS Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for ImExHS's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:IME vs TMO, DHR, IDXX: Cash-to-Debt Comparison
For the Diagnostics & Research subindustry, ImExHS's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImExHS Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ImExHS's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where ImExHS's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImExHS (ASX:IME) has a Cash-to-Debt of 5.83 as of Dec. 2025. This is 87% above median its historical median of 3.12. Over the past decade, ImExHS's Cash-to-Debt has ranged from 0.75 to 10,000.00. According to the industry distribution chart, ImExHS ranks #54 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 25.8%.
Is ImExHS's Cash-to-Debt too high?
ImExHS's current Cash-to-Debt of 5.83 is 87% above median its 10-year median of 3.12. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 10,000.00. The Medical Diagnostics & Research industry median Cash-to-Debt is 1.13. ImExHS's value of 5.83 is 415.9% above this industry median. Based on the distribution chart, ImExHS ranks #54 out of 209 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, ImExHS has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ImExHS's Cash-to-Debt compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, ImExHS ranks #54 out of 209 companies for Cash-to-Debt. This puts ImExHS in the upper half of its industry. The industry median Cash-to-Debt is 1.13. ImExHS's value of 5.83 is 415.9% above this benchmark. Historically, ImExHS's own Cash-to-Debt has ranged from 0.75 to 10,000.00 over the past decade. While the company's 10-year median is 3.12 vs. the industry median of 1.13, ImExHS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 1.13, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImExHS's current Cash-to-Debt of 5.83 is 415.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 1.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImExHS's current Cash-to-Debt is 5.83, which is 87% above median its own 10-year median of 3.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImExHS stock overvalued right now?
Based on GuruFocus' analysis, ImExHS (ASX:IME) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.51, compared to a current price of A$0.31 — trading 39.2% below its estimated fair value. The current Cash-to-Debt is 5.83, which is 87% above median its 10-year median of 3.12 and 415.9% above the Medical Diagnostics & Research industry median of 1.13. ImExHS's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For ImExHS (ASX:IME), the current Cash-to-Debt is 5.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImExHS (ASX:IME) Overvalued in 2026?
Based on GuruFocus' analysis, ImExHS stock appears to be undervalued.
The current stock price of A$0.31 is trading 39.2% below its estimated GF Value™ of A$0.51.
GuruFocus considers ImExHS to be Possible Value Trap.
Key valuation signals for ASX:IME:
Cash-to-Debt: 5.83 (87% above median its 10-year median of 3.12)
GF Value™: A$0.51 vs. price of A$0.31 (39.2% below fair value)
Industry Position: 415.9% above the Medical Diagnostics & Research median (#54 of 209)
No single metric tells the full story. See the ASX:IME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImExHS Ltd is a healthcare technology company engaged in the provision of medical imaging software and radiology services. The company develops and delivers enterprise imaging solutions, including radiology information systems and picture archiving and communication systems, as well as provides diagnostic imaging and teleradiology services to healthcare institutions. The company operates through two reportable segments: Software, which focuses on the development and sale of imaging systems and platforms, and Radiology Services, which provides diagnostic and teleradiology services to hospitals and medical facilities. It generates the majority of its revenue from the Radiology segment.
48GF Score
Get the complete analysis for ASX:IME
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IME has been successfully added to your 
